keyword
MENU ▼
Read by QxMD icon Read
search

LDV

keyword
https://www.readbyqxmd.com/read/29149722/effects-of-middle-ear-quasi-static-stiffness-on-sound-transmission-quantified-by-a-novel-3-axis-optical-force-sensor
#1
Ivo Dobrev, Jae Hoon Sim, Baktash Aqtashi, Alexander M Huber, Thomas Linder, Christof Röösli
BACKGROUND: Intra-operative quantification of the ossicle mobility could provide valuable feedback for the current status of the patient's conductive hearing. However, current methods for evaluation of middle ear mobility are mostly limited to the surgeon's subjective impression through manual palpation of the ossicles. This study investigates how middle ear transfer function is affected by stapes quasi-static stiffness of the ossicular chain. The stiffness of the middle ear is induced by a) using a novel fiber-optic 3-axis force sensor to quantify the quasi-static stiffness of the middle ear, and b) by artificial reduction of stapes mobility due to drying of the middle ear...
November 10, 2017: Hearing Research
https://www.readbyqxmd.com/read/29133244/real-world-effectiveness-of-8-weeks-treatment-with-ledipasvir-sofosbuvir-in-chronic-hepatitis-c
#2
Peter Buggisch, Johannes Vermehren, Stefan Mauss, Rainer Günther, Eckart Schott, Anita Pathil, Klaus Boeker, Tim Zimmermann, Gerlinde Teuber, Heike-Pfeiffer Vornkahl, Karl-Georg Simon, Claus Niederau, Heiner Wedemeyer, Stefan Zeuzem
BACKGROUND AND AIMS: Ledipasvir/Sofosbuvir (LDV/SOF) for 8 to 24 weeks is approved for the treatment of chronic hepatitis C virus infection (HCV). In the ION-3 study 8 weeks of LDV/SOF was non-inferior to 12 weeks in previously untreated genotype 1 (GT1) patients without cirrhosis. According to the summary of product characteristics (SmPC), 8 weeks treatment may be considered in naïve non-cirrhotic GT1-patients. However, there are only limited data on the effectiveness of 8 week regimen of LDV/SOF under real-world conditions available...
November 10, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29120906/efficacy-of-ledipasvir-sofosbuvir-plus-ribavirin-for-12-weeks-in-patients-with-chronic-hepatitis-c-genotype-3-and-compensated-liver-disease
#3
Stephan Moser, Karin Kozbial, Hermann Laferl, Angelika Schütz, Thomas Reiberger, Philipp Schwabl, Enisa Gutic, Cornelia Schwanke, Raphael Schubert, Julian Luhn, Tobias Lang, Michael Schleicher, Petra Steindl-Munda, Hans Haltmayer, Peter Ferenci, Michael Gschwantler
INTRODUCTION: In the era of direct-acting antivirals, hepatitis C virus (HCV) genotype (GT) 3 remains as the most difficult-to-treat HCV-GT. Currently, data on the efficacy of ledipasvir/sofosbuvir plus ribavirin (SOF/LDV+RBV) in GT3-infected patients are limited. We investigated the efficacy of this regimen in a real-life cohort from Austria. PATIENTS AND METHODS: A total of 55 patients with HCV-GT3 and compensated liver disease (20% treatment-experienced, 33% with cirrhosis, 7% with HIV coinfection) from four Austrian hepatitis centers received treatment with SOF/LDV+RBV for 12 weeks...
November 8, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29091342/ledipasvir-sofosbuvir-for-treatment-of-hepatitis-c-virus-in-sofosbuvir-experienced-ns5a-treatment-naive-patients-findings-from-two-randomized-trials
#4
Edward Tam, Anne F Luetkemeyer, Parvez S Mantry, Sanjaya K Satapathy, Peter Ghali, Minhee Kang, Richard Haubrich, Xianlin Shen, Liyun Ni, Gregory Camus, Amanda Copans, Lorenzo Rossaro, Bill Guyer, Robert S Brown
BACKGROUND & AIMS: We report data from two similarly designed studies that evaluated the efficacy, safety, and optimal duration of ledipasvir/sofosbuvir (LDV/SOF) ± ribavirin (RBV) for retreatment of chronic hepatitis C virus (HCV) in individuals who failed to achieve sustained virologic response (SVR) with prior SOF-based, non-NS5A inhibitor-containing regimens. METHODS: The RESCUE study enrolled HCV mono-infected adults with genotype 1 or 4. Non-cirrhotic participants were randomized to 12 weeks of LDV/SOF or LDV/SOF+RBV...
November 1, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29089577/sofosbuvir-sof-suppresses-ledipasvir-ldv-resistant-mutants-during-sof-ldv-combination-therapy-against-genotype-1b-hepatitis-c-virus-hcv
#5
Ashley N Brown, Lin Liu, Jaime L Rodriquez, Lisa Zhao, Layla Schuster, Eric Li, Gary P Wang, Michael N Neely, Walter Yamada, George L Drusano
Our objective was to identify drug interactions between ledipasvir (LDV) and sofosbuvir (SOF) against a genotype 1b replicon to determine optimal exposures for each agent that will maximize antiviral activity against susceptible and drug-resistant subpopulations. LDV and SOF were evaluated using a fully factorial experimental design in the BelloCell system. Replicon levels and drug-resistant variants were quantified at various times post-therapy for 14 days and a high-dimensional mathematical model was fit to the data...
October 31, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29073993/cost-effectiveness-analysis-of-new-hcv-treatments-in-egyptian-cirrhotic-and-non-cirrhotic-patients-a-societal-perspective
#6
Gihan Hamdy Elsisi, Asmaa Aburawash, Emam Waked
OBJECTIVES: To evaluate the cost-effectiveness of sofosbuvir (SOF) + ribavirin (RBV), SOF + daclatasvir (DCV), and SOF + ledipasvir (LDV) + RBV compared with SOF + pegylated interferon alfa (pegIFN) + RBV in the treatment of patients infected with hepatitis C virus in Egypt. METHODS: Two Markov models were developed on the basis of the Egyptian clinical data and practice and were derived from published sources. The clinical parameters were derived from two sources: the Egypt multicenter national treatment program and previously published randomized clinical trials...
September 2017: Value in Health Regional Issues
https://www.readbyqxmd.com/read/29063473/comparing-aspheric-ablation-profile-with-standard-corneal-ablation-for-correction-of-myopia-and-myopic-astigmatism-a-contralateral-eye-study
#7
Mohammad Ghoreishi, Afsaneh Naderi Beni, Zahra Naderi Beni, Alireza Zandi, Farzan Kianersi
The purpose of this study is to compare visual outcomes of myopic refractive surgery, using tissue saving (TS), a standard ablation profile by a Technolas 217z100, and aberration smart ablation (ASA), an aspheric algorithm by a MEL 80 excimer laser in two eyes of one patient. In this prospective interventional paired-eye controlled study, a total of 100 eyes of 50 participants with myopia with or without astigmatism underwent thin-flap Femto-LASIK, using a Femto LDV femtosecond laser (Ziemer Ophthalmic Systems AG, Port, Switzerland)...
December 2017: Lasers in Medical Science
https://www.readbyqxmd.com/read/29062777/comparison-of-visual-performance-recovery-after-thin-flap-lasik-with-4-femtosecond-lasers
#8
Jing Zhang, Yue-Hua Zhou, Yan Zheng, Qian Liu
AIM: To compare the speed of visual recovery following myopic thin-flap LASIK with four femtosecond lasers. METHODS: Eighty-eight eyes of 46 patients who were consecutively scheduled for bilateral LASIK with the IntraLase FS60 (Group 1), Femto LDV Crystal Line (Group 2), Wavelight FS200 (Group 3) and VisuMax (Group 4) femtosecond lasers were enrolled in. Monocular uncorrected distance visual acuity (UDVA), best-corrected distant visual acuity (CDVA), refraction, contrast sensitivity and higher-order aberrations (HOAs) were evaluated at 1, 3d, 1wk and 1mo postoperatively...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/29057082/high-sustained-virological-response-rates-using-imported-generic-direct-acting-antiviral-treatment-for-hepatitis-c
#9
EDITORIAL
Andrew Hill, Giten Khwairakpam, James Wang, Sergey Golovin, Julia Dragunova, Rachel Smith, Vicky Houghton-Price, Roxanna Korologou-Linden, Sanjay Nath, Anna Savage, Greg Jefferys
BACKGROUND: High prices of direct acting antivirals (DAAs) for hepatitis C virus (HCV) can lead to restrictions on access to treatment in high- and middle-income countries. An increasing number of people in these countries are treating their HCV infection with generic drugs produced in India, China, Bangladesh or Egypt. This analysis assessed the efficacy of generic imported DAAs. METHODS: Patients sourced generic versions of sofosbuvir (SOF), ledipasvir (LDV) and daclatasvir (DCV) from suppliers in India, Bangladesh, China and Egypt via three buyers' clubs...
October 1, 2017: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29054109/influence-of-backside-loading-on-the-floating-mass-transducer-an-in-vitro-experimental-study
#10
Antoniu-Oreste Gostian, Martin Sylvester Otte, David Pazen, Magdalene Ortmann, David Schwarz, Karl Bernd Hüttenbrink, Dirk Beutner
HYPOTHESIS: The vibration of the floating mass transducer (FMT) of a single active middle-ear implant (AMEI) is distinctly influenced by the properties of the material coupled to its back side. BACKGROUND: In round window vibroplasty, the FMT needs to be padded against the surrounding bone opposite from the round window membrane. This represents one factor influencing its performance as a round window driver. Therefore, we examined the effects of different materials linked to the back side of an FMT on its vibration range...
October 20, 2017: Clinical Otolaryngology
https://www.readbyqxmd.com/read/29053909/impact-of-ledipasvir-sofosbuvir-on-the-work-productivity-of-genotype-1-chronic-hepatitis-c-patients-in-asia
#11
Zobair M Younossi, Henry Lik Yuen Chan, Yock Young Dan, Mei Hsuan Lee, Young-Suk Lim, Eliza Kruger, Seng Chuen Tan
Chronic, untreated hepatitis C virus (HCV) infection is associated with a poor clinical prognosis and a detrimental impact on patients' lives, including on work productivity. To estimate the value of productivity losses due to genotype 1 (GT1) HCV infection in Hong Kong, Singapore, South Korea and Taiwan and to estimate the potential productivity gains associated with treating patients with ledipasvir/sofosbuvir (LDV/SOF) therapy,an economic model was developed with a time horizon of one year. HCV patients entered the model at 12 weeks post-treatment, having achieved or not achieved sustained virological response (SVR)...
October 20, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29020359/sofosbuvir-based-interferon-free-direct-acting-antiviral-regimens-for-heart-transplant-recipients-with-chronic-hepatitis-c-virus-infection
#12
Chen-Hua Liu, Yih-Sharng Chen, Sheoi-Shen Wang, Chun-Jen Liu, Tung-Hung Su, Hung-Chih Yang, Chun-Ming Hong, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao
We assessed the effectiveness and safety of sofosbuvir (SOF) combined with ledipasvir (LDV) or daclatasvir (DCV) in 12 heart transplant recipients with chronic hepatitis C virus (HCV). The sustained virologic response (SVR12) rate was 100% [95% CI: 75.8%-100%]. All patients tolerated treatment well without interruption, death or serious adverse events.
September 4, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28994393/quantitative-measurement-of-hcv-core-antigen-for-management-of-interferon-free-therapy-in-hcv-infected-patients
#13
Mariusz Łucejko, Robert Flisiak
BACKGROUND: According to current recommendations diagnosis and management of HCV infection need detection and quantification of nucleic acids. In the era of direct acting antivirals (DAA) it is essential to develop inexpensive and simple method replacing polymerase chain reaction. Since there is no available data on HCV core antigen (HCVcAg) versus HCV RNA kinetics in the early phase of treatment with DAA, we carried out this study to evaluate possible application of HCVcAg quantitative measurement for management of HCV infection...
October 10, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28988445/effect-of-cochlear-implantation-on-middle-ear-function-a-three-month-prospective-study
#14
Joseph D Wasson, Luke Campbell, Scott Chambers, Amy Hampson, Robert J S Briggs, Stephen J O'Leary
OBJECTIVES/HYPOTHESIS: To determine if cochlear implantation has a delayed effect on the middle ear conductive hearing mechanism by measuring laser Doppler vibrometry (LDV) of the tympanic membrane (TM) in both implanted and contralateral control ears preoperatively and 3 months postoperatively, and then comparing the relative change in LDV outcome measures between implanted and control ears. STUDY DESIGN: Prospective cohort study. METHODS: Eleven preoperative adult unilateral cochlear implant recipients in previously unoperated ears with normal anatomy and aerated temporal bones were included in this study...
October 8, 2017: Laryngoscope
https://www.readbyqxmd.com/read/28984067/resistance-characterization-of-ledipasvir-and-velpatasvir-in-hepatitis-c-virus-genotype-4
#15
Gregory Camus, Bin Han, Tarik Asselah, David Hsieh, Hadas Dvory-Sobol, Julia Lu, Evguenia Svarovskaia, Ross Martin, Bandita Parhy, Michael Miller, Diana M Brainard, Kathryn Kersey, Armand Abergel, Hongmei Mo
HCV genotype 4 (GT4) has often been overlooked in drug development, even though it infects approximately 20 million people worldwide. Ledipasvir/sofosbuvir and sofosbuvir/velpatasvir were highly efficacious in GT4 HCV infected patients from GS-US-337-1119 and GS-US-342-1138. Here we characterize the resistance profile of ledipasvir (LDV) and velpatasvir (VEL) in patients with GT4 HCV infection. NS5A deep-sequencing was performed for 454 patients infected with HCV GT4 at baseline, including 44 patients enrolled in GS-US-337-1119 and 116 patients enrolled in GS-US-342-1138, and at relapse for patients with virologic failure...
October 6, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28964568/sound-wave-propagation-on-the-human-skull-surface-with-bone-conduction-stimulation
#16
Ivo Dobrev, Jae Hoon Sim, Stefan Stenfelt, Sebastian Ihrle, Rahel Gerig, Flurin Pfiffner, Albrecht Eiber, Alexander M Huber, Christof Röösli
BACKGROUND: Bone conduction (BC) is an alternative to air conduction to stimulate the inner ear. In general, the stimulation for BC occurs on a specific location directly on the skull bone or through the skin covering the skull bone. The stimulation propagates to the ipsilateral and contralateral cochlea, mainly via the skull bone and possibly via other skull contents. This study aims to investigate the wave propagation on the surface of the skull bone during BC stimulation at the forehead and at ipsilateral mastoid...
September 23, 2017: Hearing Research
https://www.readbyqxmd.com/read/28964443/cost-utility-of-elbasvir-grazoprevir-in-patients-with-chronic-hepatitis-c-genotype-1-infection
#17
COMPARATIVE STUDY
Shelby Corman, Elamin H Elbasha, Steven N Michalopoulos, Chizoba Nwankwo
OBJECTIVE: To evaluate the cost-utility of treatment with elbasvir/grazoprevir (EBR/GZR) regimens compared with ledipasvir/sofosbuvir (LDV/SOF), ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin (3D ± RBV), and sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C genotype (GT) 1 infection. METHODS: A Markov cohort state-transition model was constructed to evaluate the cost-utility of EBR/GZR ± RBV over a lifetime time horizon from the payer perspective...
September 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28957984/health-related-quality-of-life-in-adolescent-patients-with-hepatitis-c-genotype-1-treated-with-sofosbuvir-and-ledipasvir
#18
Zobair M Younossi, Maria Stepanova, William Balistreri, Kathleen Schwarz, Karen F Murray, Philip Rosenthal, Sanjay Bansal, Sharon Hunt
OBJECTIVE: To assess the impact of treatment with ledipasvir/sofosbuvir (LDV/SOF) on the health-related quality of life (HRQL) of pediatric patients with chronic hepatitis C virus (HCV) infection. METHODS: Adolescents (12-17 years) with HCV were treated with LDV/SOF (90 mg/400 mg daily) for 12 weeks. HRQL was assessed using the PedsQLv4.0-SF15 completed by the children and caregivers before, during, and after treatment. RESULTS: We included 100 adolescents with HCV genotype 1 infection [14...
September 27, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/28935852/single-center-experience-in-pre-transplant-hepatitis-c-virus-hcv-treatment-among-living-donor-liver-transplant-candidates-bridging-the-direct-acting-antivirals-daa
#19
Ashwini M Niranjan-Azadi, Gokhan Kabacam, Christine M Durand, Saad Anjum, Behnam Saberi, Nabil N Dagher, Benjamin Philosophe, Ahmet Gurakar
BACKGROUND Treatment with DAAs before deceased donor liver transplantation has been shown to be an effective strategy to prevent post-transplant HCV recurrence, with a 95% cure-rate among individuals who achieve undetectable HCV VL for ≥30 days pre- transplant. This strategy has not been evaluated in LDLT. MATERIAL AND METHODS We evaluated outcomes in LDLT recipients treated with DAAs pre-transplant and bridged with 4 weeks of post-transplant SOF. All cases of LDLT at Johns Hopkins (1/1/2014-3/1/15) were retrospectively reviewed...
September 22, 2017: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://www.readbyqxmd.com/read/28923637/ledipasvir%C3%A2-sofosbuvir-for-liver-transplant-recipients-with-recurrent-hepatitis-c-a-systematic-review-and-meta-analysis
#20
H-T Liao, P Tan, J-W Huang, K-F Yuan
INTRODUCTION: Studies focusing on the efficacy and safety of ledipasvir (LDV) + sofosbuvir (SOF) therapy in liver transplant (LT) recipients with hepatitis C virus (HCV) recurrence are still limited. Therefore, the aim of our work was to perform a systematic review and meta-analysis to evaluate outcome data of LDV + SOF therapy in LT recipients. METHODS: Multiple databases were systematically searched for eligible studies. We included studies reporting sustained virological response 12 weeks after treatment (SVR12) and treatment-related adverse events (AEs) in LT recipients treated with LDV + SOF ± ribavirin (RBV) for HCV recurrence...
October 2017: Transplantation Proceedings
keyword
keyword
95665
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"